TY - JOUR
T1 - The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin system inhibitor treatment
T2 - a post hoc analysis
AU - Scholtes, Rosalie A.
AU - van Raalte, Daniël H.
AU - Correa-Rotter, Ricardo
AU - Toto, Robert D.
AU - Heerspink, Hiddo J.L.
AU - Cain, Valerie
AU - Sjöström, C. David
AU - Sartipy, Peter
AU - Stefánsson, Bergur V.
N1 - Funding Information:
The authors thank all the site investigators and patients who participated in the reported dapagliflozin studies. This study was funded by AstraZeneca. Editorial support and some medical writing support, which were in accordance with Good Publication Practice (GPP3) guidelines, were provided by Advait Joshi, PhD and Steven Tresker, both of Cactus Communications, and were funded by AstraZeneca. The sponsor was involved in the study design; collection, analysis and interpretation of data; report writing; and the decision to submit the manuscript for publication. This analysis was previously presented as an abstract and a poster at the European Association for the Study of Diabetes (EASD) 2018 meeting.
Funding Information:
The authors thank all the site investigators and patients who participated in the reported dapagliflozin studies. This study was funded by AstraZeneca. Editorial support and some medical writing support, which were in accordance with Good Publication Practice (GPP3) guidelines, were provided by Advait Joshi, PhD and Steven Tresker, both of Cactus Communications, and were funded by AstraZeneca. The sponsor was involved in the study design; collection, analysis and interpretation of data; report writing; and the decision to submit the manuscript for publication. This analysis was previously presented as an abstract and a poster at the European Association for the Study of Diabetes (EASD) 2018 meeting.
Publisher Copyright:
© 2019 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Aims: Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium-glucose co-transporter-2 inhibitors reduce albuminuria and may complement RASi by offering additional renal protection. This post hoc analysis investigated the effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes (T2D) with increased albuminuria treated with or without RASi at baseline. Materials and methods: We evaluated the effects of dapagliflozin 10 mg/day over 12–24 weeks across 13 placebo-controlled studies in patients with T2D with a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g at baseline. Patients were divided into two subgroups based on treatment with or without RASi at baseline. Results: Compared with patients with RASi at baseline (n = 957), patients without RASi (n = 302) were younger, had a shorter duration of diabetes (7 vs. 12 years), higher estimated glomerular filtration rate (eGFR) and lower UACR, serum uric acid (sUA), body weight and systolic blood pressure. Placebo-adjusted treatment effects of dapagliflozin on UACR, eGFR, glycated haemoglobin and haematocrit over 24 weeks were similar across groups. Mean reductions in body weight and sUA were more distinct in patients without RASi treatment at baseline. Conclusions: Treatment with dapagliflozin over 24 weeks provides similar clinically relevant improvements in metabolic and haemodynamic parameters, and similar reductions in UACR, in patients with T2D with elevated albuminuria treated with or without RASi at baseline.
AB - Aims: Renin-angiotensin system inhibitors (RASi) are the most effective treatments for diabetic kidney disease but significant residual renal risk remains, possibly because of other mechanisms of kidney disease progression unrelated to RAS that may be present. Sodium-glucose co-transporter-2 inhibitors reduce albuminuria and may complement RASi by offering additional renal protection. This post hoc analysis investigated the effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes (T2D) with increased albuminuria treated with or without RASi at baseline. Materials and methods: We evaluated the effects of dapagliflozin 10 mg/day over 12–24 weeks across 13 placebo-controlled studies in patients with T2D with a urinary albumin-to-creatinine ratio (UACR) ≥30 mg/g at baseline. Patients were divided into two subgroups based on treatment with or without RASi at baseline. Results: Compared with patients with RASi at baseline (n = 957), patients without RASi (n = 302) were younger, had a shorter duration of diabetes (7 vs. 12 years), higher estimated glomerular filtration rate (eGFR) and lower UACR, serum uric acid (sUA), body weight and systolic blood pressure. Placebo-adjusted treatment effects of dapagliflozin on UACR, eGFR, glycated haemoglobin and haematocrit over 24 weeks were similar across groups. Mean reductions in body weight and sUA were more distinct in patients without RASi treatment at baseline. Conclusions: Treatment with dapagliflozin over 24 weeks provides similar clinically relevant improvements in metabolic and haemodynamic parameters, and similar reductions in UACR, in patients with T2D with elevated albuminuria treated with or without RASi at baseline.
KW - RASi
KW - SGLT-2 inhibitors
KW - cardiac and renal risk factors
KW - dapagliflozin
KW - type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85076732648&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85076732648&partnerID=8YFLogxK
U2 - 10.1111/dom.13923
DO - 10.1111/dom.13923
M3 - Article
C2 - 31742881
AN - SCOPUS:85076732648
VL - 22
SP - 549
EP - 556
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 4
ER -